
InVision Medical Technology
AI Diagnosis of Heart Disease
- Founded
- 2022
- Status
- Active
- Stage
- Early
- Team size
- 2
- Location
- San Francisco, CA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Healthcare
About InVision Medical Technology
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
FDA clearances
2 510(k) clearances on record, 2024 to 2025.
- InVision Precision Cardiac Amyloid
- InVision Precision LVEF (LVEF)
K232331, K243866
Source: FDA 510(k) database via openFDA.
Company data compiled and maintained by Healthcare Discovery.
